Papillary Renal Cell Carcinoma: Demographics, Survival Analysis, Racial Disparities, and Genomic Landscape.

IF 1.9 Q3 ONCOLOGY Journal of Kidney Cancer and VHL Pub Date : 2023-12-26 eCollection Date: 2023-01-01 DOI:10.15586/jkcvhl.v10i4.294
Asad Ullah, Abdul Qahar Khan Yasinzai, Naema Daino, Bisma Tareen, Zulfiqar Haider Jogezai, Haleema Sadia, Nimra Jamil, Girahnaz Baloch, Adil Karim, Kaleemullah Badini, Agha Wali, Abdul Waheed, Marjan Khan, Bina Asif, Kaleemullah Kakar, Saleh Heneidi, Feroze Sidhwa, Nabin R Karki
{"title":"Papillary Renal Cell Carcinoma: Demographics, Survival Analysis, Racial Disparities, and Genomic Landscape.","authors":"Asad Ullah, Abdul Qahar Khan Yasinzai, Naema Daino, Bisma Tareen, Zulfiqar Haider Jogezai, Haleema Sadia, Nimra Jamil, Girahnaz Baloch, Adil Karim, Kaleemullah Badini, Agha Wali, Abdul Waheed, Marjan Khan, Bina Asif, Kaleemullah Kakar, Saleh Heneidi, Feroze Sidhwa, Nabin R Karki","doi":"10.15586/jkcvhl.v10i4.294","DOIUrl":null,"url":null,"abstract":"<p><p>Papillary renal cell carcinoma (PRCC) is the second most common histological subtype of renal cell cancer. This research aims to present a large database study highlighting the demographic, clinical, and pathological factors, racial disparities, prognosis, and survival of PRCC. The clinical and demographic data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database, and molecular data was cured from the Catalogue Of Somatic Mutations in Cancer (COSMIC) database. PRCC had a median age of diagnosis at 64 years, with a higher incidence in men (77%), and Whites (68%). 70.3% of cases were Grades I-IV (13, 53, 31, and 3%, respectively). In patients with known data, 85% were localized to the kidney, and 84% of cases were 7 cm in size. No metastasis occurred in 97% of the known data. The most common treatment offered was surgical resection (9%). The 5-year overall survival was 79%, with patients undergoing surgery having a 90.6% 5-year survival. Multivariable analysis revealed age > 60 years, Black race, poor histologic differentiation, distant metastases, and tumor size > 10 cm as independent risk factors for mortality. The most common mutations identified from the COSMIC database were MET, KMT2D, KMT2C, ARID1A, and SPEN. PRCC affects male individuals in the sixth decade of life. Increased age, Black race, distant metastases, and tumors > 10 cm are associated with a worse prognosis. Surgical resection offers a favorable survival outcome. Next-generation sequencing (NGS) could identify potentially targetable alterations and future personalized therapeutic approaches.</p>","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"10 4","pages":"33-42"},"PeriodicalIF":1.9000,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10755762/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Kidney Cancer and VHL","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15586/jkcvhl.v10i4.294","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Papillary renal cell carcinoma (PRCC) is the second most common histological subtype of renal cell cancer. This research aims to present a large database study highlighting the demographic, clinical, and pathological factors, racial disparities, prognosis, and survival of PRCC. The clinical and demographic data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database, and molecular data was cured from the Catalogue Of Somatic Mutations in Cancer (COSMIC) database. PRCC had a median age of diagnosis at 64 years, with a higher incidence in men (77%), and Whites (68%). 70.3% of cases were Grades I-IV (13, 53, 31, and 3%, respectively). In patients with known data, 85% were localized to the kidney, and 84% of cases were 7 cm in size. No metastasis occurred in 97% of the known data. The most common treatment offered was surgical resection (9%). The 5-year overall survival was 79%, with patients undergoing surgery having a 90.6% 5-year survival. Multivariable analysis revealed age > 60 years, Black race, poor histologic differentiation, distant metastases, and tumor size > 10 cm as independent risk factors for mortality. The most common mutations identified from the COSMIC database were MET, KMT2D, KMT2C, ARID1A, and SPEN. PRCC affects male individuals in the sixth decade of life. Increased age, Black race, distant metastases, and tumors > 10 cm are associated with a worse prognosis. Surgical resection offers a favorable survival outcome. Next-generation sequencing (NGS) could identify potentially targetable alterations and future personalized therapeutic approaches.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乳头状肾细胞癌:人口统计学、生存分析、种族差异和基因组图谱。
乳头状肾细胞癌(PRCC)是肾细胞癌中第二常见的组织学亚型。本研究旨在介绍一项大型数据库研究,重点关注PRCC的人口统计学、临床和病理学因素、种族差异、预后和存活率。临床和人口统计学数据来自监测、流行病学和最终结果(SEER)数据库,分子数据来自癌症体细胞突变目录(COSMIC)数据库。PRC的中位诊断年龄为64岁,男性(77%)和白人(68%)的发病率较高。70.3%的病例属于I-IV级(分别为13、53、31和3%)。在已知数据的患者中,85%的病例位于肾脏,84%的病例大小为7厘米。97%的已知数据没有发生转移。最常见的治疗方法是手术切除(9%)。5年总生存率为79%,接受手术的患者5年生存率为90.6%。多变量分析显示,年龄大于 60 岁、黑人、组织学分化不良、远处转移和肿瘤大小大于 10 厘米是导致死亡的独立风险因素。从COSMIC数据库中发现的最常见突变是MET、KMT2D、KMT2C、ARID1A和SPEN。PRC多发于60岁左右的男性。年龄增大、黑人、远处转移和肿瘤大于 10 厘米与预后较差有关。手术切除的生存率较高。下一代测序(NGS)可确定潜在的靶向性改变和未来的个性化治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
6.20%
发文量
22
审稿时长
4 weeks
期刊最新文献
Avoidable Benign Kidney Tumor Resections-Data from a Tertiary Care Cancer Institute. Primary Nonseminomatous Germ Cell Tumor of Kidney: An Uncommon Renal Neoplasm. Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation (osteosarcomatous and chondrosarcomatous differentiation)-A Case Report and Comprehensive Review. An Uncommon Case of Sinonasal Adenoid Cystic Carcinoma Metastatic to the Kidney Treated with Metastasectomy. Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical Trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1